AbbVie's drug stopped migraines that had already started within two hours in one in four participants in the clinical trial
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
FDA consultants have unanimously approved the registration of Eli Lilly's drug for Alzheimer's disease.
